A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against<i>Plasmodium falciparum</i><i>Malaria</i>

Abstract

A recombinant vaccine based on fusion of the circumsporozoite protein and HBsAg plus a potent adjuvant can protect against experimental challenge with P. falciparum sporozoites. After additional studies of protective immunity and the vaccination schedule, field trials are indicated for this new vaccine against P. falciparum malaria.